TRUQAP, along with fulvestrant, is used to treat adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced, or metastatic breast cancer.
This is specifically for patients who have alterations in PIK3CA/AKT1/PTEN, identified by an FDA-approved test.
This treatment is recommended after progression on at least one endocrine-based regimen in the metastatic setting or recurrence within 12 months of completing adjuvant therapy.
Capivasertib is a medicine that blocks three forms of a protein called AKT, which is involved in cell processes.
It stops the activation of AKT and its effects on other substances in the body.
In tumors, AKT gets activated due to various reasons like mutations in AKT1, problems with PTEN function, or mutations in PIK3CA.
Capivasertib was tested in the lab (in vitro) and it slowed down the growth of breast cancer cells, especially those with certain mutations. In live tests (in vivo), capivasertib, by itself and with fulvestrant, slowed down the growth of tumors in mice, specifically those with estrogen receptor positive breast cancer and alterations in PIK3CA, AKT1, and PTEN.